Business Context and Reporting Period
Company: resTORbio, Inc. (Note: Input metadata referenced "Adicet Bio," but the filing text identifies the registrant as resTORbio, Inc.)
Reporting Period: Fiscal year ended December 31, 2017.
Business Overview: resTORbio is a clinical-stage biopharmaceutical company focused on developing therapeutics for aging-related diseases. Its lead program, RTB101 (a TORC1 inhibitor), is being developed alone or in combination with everolimus to reduce the incidence of respiratory tract infections (RTIs) in the elderly by enhancing immune function. The company licensed the worldwide rights to this program from Novartis in March 2017. As of the filing date, the company had no approved products and had not generated any revenue.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2017 | Inception (July 5, 2016) to Dec 31, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(33.8) million | $(1) thousand |
| Operating Expenses | $18.9 million | $1 thousand |
| Research & Development (R&D) | $16.8 million | $0 |
| General & Administrative (G&A) | $2.0 million | $1 thousand |
| Cash and Cash Equivalents (Dec 31, 2017) | $53.3 million | $0 |
| Working Capital (Dec 31, 2017) | $49.7 million | N/A |
| Total Liabilities (Dec 31, 2017) | $5.5 million | $0 |
| Accumulated Deficit (Dec 31, 2017) | $(33.8) million | $(1) thousand |
Note: The company reported no debt as of December 31, 2017. Total liabilities consisted of accounts payable and accrued liabilities.
Material Changes vs. Prior Period
- Operational Commencement: The company was incorporated in July 2016 but did not commence significant operations until March 2017 upon licensing the RTB101 program from Novartis. Consequently, 2016 financial activity was negligible compared to 2017.
- Expense Surge: Total operating expenses increased from $1,000 in 2016 to $18.9 million in 2017. This was driven primarily by R&D costs of $16.8 million, including $10.0 million for clinical trials (Phase 2b), $3.9 million related to the Novartis license agreement, and $1.3 million for contract research.
- Non-Cash Charges: The 2017 net loss included a significant non-cash charge of $14.9 million representing the change in fair value of tranche rights liability associated with redeemable convertible preferred stock.
- Cash Position: Cash and cash equivalents increased from $0 to $53.3 million, funded by $64.4 million in net cash provided by financing activities (issuance of Series A and Series B preferred stock).
Guidance, Outlook, and Risks
Outlook and Milestones:
- Clinical Development: The company is conducting a Phase 2b clinical trial for RTB101 alone and in combination with everolimus. Top-line data is expected in the second half of 2018.
- Future Plans: If Phase 2b results are positive, the company plans to initiate Phase 3 pivotal trials in 2019, with a goal to submit a New Drug Application (NDA) to the FDA in 2020.
- Liquidity: Management believes that existing cash ($53.3 million) combined with net proceeds from the Initial Public Offering (IPO) completed in January 2018 ($89.4 million) will fund operations through 2020.
Risks and Contingencies:
- Capital Needs: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional funding to complete development and commercialization.
- Regulatory Risk: Success depends entirely on obtaining regulatory approval for RTB101. There is no guarantee that clinical trials will demonstrate sufficient efficacy or safety.
- Intellectual Property: The company relies on an exclusive license from Novartis. Termination of this license or failure to meet milestones could severely harm the business.
- Third-Party Dependence: The company relies on third-party contract research organizations (CROs) and contract manufacturing organizations (CMOs) for clinical trials and drug supply.
Key Facts for Investor Verification
- Revenue Status: Verify that the company has generated zero revenue to date and has no approved products.
- Cash Runway: Confirm the sufficiency of the $89.4 million IPO proceeds (closed Jan 2018) combined with year-end 2017 cash to fund operations through 2020 as projected.
- Clinical Trial Progress: Monitor the status and top-line data release of the ongoing Phase 2b clinical trial, expected in H2 2018.
- Novartis License Obligations: Review the milestone payment structure (up to $4.3M clinical, $24M regulatory for first indication, $18M for second, and $125M commercial) and royalty obligations (mid-single to low-teen digit percentages).
- Non-Cash Loss Components: Note that a significant portion of the 2017 net loss ($14.9M) was a non-cash fair value adjustment, not an operating cash outflow.